News & Updates

The use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) among patients with diabetes and cancer results in significantly reduced mortality and hospitalizations relative to treatment with metformin, a study has shown.

A study from the US finds that compared with afternoon infusions, morning infusions of immune checkpoint inhibitors (ICI) confer a modest but clinically meaningful overall survival (OS) benefit to patients with non-small-cell lung cancer (NSCLC).

Treatment with gedatolisib plus fulvestrant, with or without palbociclib, significantly improves progression-free survival (PFS) in patients with HR+/HER2– PIK3CA wild-type (WT) advanced breast cancer (ABC) compared with fulvestrant alone, according to the VIKTORIA-1 trial presented at ESMO Breast Cancer 2026.